Breakthrough Genomic Test Could Spare Millions of Breast Cancer Patients from Chemotherapy
A landmark genomic testing technology has been announced that could more accurately assess which breast cancer patients need chemotherapy, potentially sparing millions from unnecessary treatment.
Traditionally, doctors have recommended chemotherapy for most breast cancer patients after surgery to reduce recurrence risk. However, studies show a significant portion of patients actually do not need chemotherapy to maintain good outcomes. The new genomic test analyzes expression patterns of specific genes in tumor samples to more accurately predict which patients fall into the low-recurrence-risk category.
Clinical trial data shows that using this technology, approximately 30% to 40% of patients who would otherwise be recommended for chemotherapy can safely avoid it. This significantly reduces patients’ side effects and financial burden while conserving medical resources.
Oncology experts say this technology represents a major advance in precision medicine for cancer. Through genomic approaches, doctors can develop more personalized treatment plans for each patient, moving away from a one-size-fits-all treatment model.
The test is currently seeking regulatory approval in multiple countries and is expected to enter clinical use within the next year.